Clinical outcomes and bacterial characteristics of carbapenem-resistant Klebsiella pneumoniae complex among patients from different global regions (CRACKLE-2) : a prospective, multicentre, cohort study
Copyright © 2022 Elsevier Ltd. All rights reserved..
BACKGROUND: Carbapenem-resistant Klebsiella pneumoniae (CRKP) is a global threat. We therefore analysed the bacterial characteristics of CRKP infections and the clinical outcomes of patients with CRKP infections across different countries.
METHODS: In this prospective, multicentre, cohort study (CRACKLE-2), hospitalised patients with cultures positive for CRKP were recruited from 71 hospitals in Argentina, Australia, Chile, China, Colombia, Lebanon, Singapore, and the USA. The first culture positive for CRKP was included for each unique patient. Clinical data on post-hospitalisation death and readmission were collected from health records, and whole genome sequencing was done on all isolates. The primary outcome was a desirability of outcome ranking at 30 days after the index culture, and, along with bacterial characteristics and 30-day all-cause mortality (a key secondary outcome), was compared between patients from China, South America, and the USA. The desirability of outcome ranking was adjusted for location before admission, Charlson comorbidity index, age at culture, Pitt bacteremia score, and anatomical culture source through inverse probability weighting; mortality was adjusted for the same confounders, plus region where relevant, through multivariable logistic regression. This study is registered at ClinicalTrials.gov, NCT03646227, and is complete.
FINDINGS: Between June 13, 2017, and Nov 30, 2018, 991 patients were enrolled, of whom 502 (51%) met the criteria for CRKP infection and 489 (49%) had positive cultures that were considered colonisation. We observed little intra-country genetic variation in CRKP. Infected patients from the USA were more acutely ill than were patients from China or South America (median Pitt bacteremia score 3 [IQR 2-6] vs 2 [0-4] vs 2 [0-4]) and had more comorbidities (median Charlson comorbidity index 3 [IQR 2-5] vs 1 [0-3] vs 1 [0-2]). Adjusted desirability of outcome ranking outcomes were similar in infected patients from China (n=246), South America (n=109), and the USA (n=130); the estimates were 53% (95% CI 42-65) for China versus South America, 50% (41-61) for the USA versus China, and 53% (41-66) for the USA versus South America. In patients with CRKP infections, unadjusted 30-day mortality was lower in China (12%, 95% CI 8-16; 29 of 246) than in the USA (23%, 16-30; 30 of 130) and South America (28%, 20-37; 31 of 109). Adjusted 30-day all-cause mortality was higher in South America than in China (adjusted odds ratio [aOR] 4·82, 95% CI 2·22-10·50) and the USA (aOR 3·34, 1·50-7·47), with the mortality difference between the USA and China no longer being significant (aOR 1·44, 0·70-2·96).
INTERPRETATION: Global CRKP epidemics have important regional differences in patients' baseline characteristics and clinical outcomes, and in bacterial characteristics. Research findings from one region might not be generalisable to other regions.
FUNDING: The National Institutes of Health.
| Errataetall: |
CommentIn: Lancet Infect Dis. 2022 Mar;22(3):309-310. - PMID 34767752 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
|---|---|
| Enthalten in: |
The Lancet. Infectious diseases - 22(2022), 3 vom: 02. März, Seite 401-412 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Wang, Minggui [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anti-Bacterial Agents |
|---|
| Anmerkungen: |
Date Completed 21.04.2022 Date Revised 02.03.2023 published: Print-Electronic ClinicalTrials.gov: NCT03646227 CommentIn: Lancet Infect Dis. 2022 Mar;22(3):309-310. - PMID 34767752 Citation Status MEDLINE |
|---|
| doi: |
10.1016/S1473-3099(21)00399-6 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM333055780 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM333055780 | ||
| 003 | DE-627 | ||
| 005 | 20231225220841.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/S1473-3099(21)00399-6 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1110.xml |
| 035 | |a (DE-627)NLM333055780 | ||
| 035 | |a (NLM)34767753 | ||
| 035 | |a (PII)S1473-3099(21)00399-6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Wang, Minggui |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clinical outcomes and bacterial characteristics of carbapenem-resistant Klebsiella pneumoniae complex among patients from different global regions (CRACKLE-2) |b a prospective, multicentre, cohort study |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.04.2022 | ||
| 500 | |a Date Revised 02.03.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT03646227 | ||
| 500 | |a CommentIn: Lancet Infect Dis. 2022 Mar;22(3):309-310. - PMID 34767752 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 Elsevier Ltd. All rights reserved. | ||
| 520 | |a BACKGROUND: Carbapenem-resistant Klebsiella pneumoniae (CRKP) is a global threat. We therefore analysed the bacterial characteristics of CRKP infections and the clinical outcomes of patients with CRKP infections across different countries | ||
| 520 | |a METHODS: In this prospective, multicentre, cohort study (CRACKLE-2), hospitalised patients with cultures positive for CRKP were recruited from 71 hospitals in Argentina, Australia, Chile, China, Colombia, Lebanon, Singapore, and the USA. The first culture positive for CRKP was included for each unique patient. Clinical data on post-hospitalisation death and readmission were collected from health records, and whole genome sequencing was done on all isolates. The primary outcome was a desirability of outcome ranking at 30 days after the index culture, and, along with bacterial characteristics and 30-day all-cause mortality (a key secondary outcome), was compared between patients from China, South America, and the USA. The desirability of outcome ranking was adjusted for location before admission, Charlson comorbidity index, age at culture, Pitt bacteremia score, and anatomical culture source through inverse probability weighting; mortality was adjusted for the same confounders, plus region where relevant, through multivariable logistic regression. This study is registered at ClinicalTrials.gov, NCT03646227, and is complete | ||
| 520 | |a FINDINGS: Between June 13, 2017, and Nov 30, 2018, 991 patients were enrolled, of whom 502 (51%) met the criteria for CRKP infection and 489 (49%) had positive cultures that were considered colonisation. We observed little intra-country genetic variation in CRKP. Infected patients from the USA were more acutely ill than were patients from China or South America (median Pitt bacteremia score 3 [IQR 2-6] vs 2 [0-4] vs 2 [0-4]) and had more comorbidities (median Charlson comorbidity index 3 [IQR 2-5] vs 1 [0-3] vs 1 [0-2]). Adjusted desirability of outcome ranking outcomes were similar in infected patients from China (n=246), South America (n=109), and the USA (n=130); the estimates were 53% (95% CI 42-65) for China versus South America, 50% (41-61) for the USA versus China, and 53% (41-66) for the USA versus South America. In patients with CRKP infections, unadjusted 30-day mortality was lower in China (12%, 95% CI 8-16; 29 of 246) than in the USA (23%, 16-30; 30 of 130) and South America (28%, 20-37; 31 of 109). Adjusted 30-day all-cause mortality was higher in South America than in China (adjusted odds ratio [aOR] 4·82, 95% CI 2·22-10·50) and the USA (aOR 3·34, 1·50-7·47), with the mortality difference between the USA and China no longer being significant (aOR 1·44, 0·70-2·96) | ||
| 520 | |a INTERPRETATION: Global CRKP epidemics have important regional differences in patients' baseline characteristics and clinical outcomes, and in bacterial characteristics. Research findings from one region might not be generalisable to other regions | ||
| 520 | |a FUNDING: The National Institutes of Health | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Anti-Bacterial Agents |2 NLM | |
| 650 | 7 | |a Carbapenems |2 NLM | |
| 700 | 1 | |a Earley, Michelle |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Liang |e verfasserin |4 aut | |
| 700 | 1 | |a Hanson, Blake M |e verfasserin |4 aut | |
| 700 | 1 | |a Yu, Yunsong |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Zhengyin |e verfasserin |4 aut | |
| 700 | 1 | |a Salcedo, Soraya |e verfasserin |4 aut | |
| 700 | 1 | |a Cober, Eric |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Lanjuan |e verfasserin |4 aut | |
| 700 | 1 | |a Kanj, Souha S |e verfasserin |4 aut | |
| 700 | 1 | |a Gao, Hainv |e verfasserin |4 aut | |
| 700 | 1 | |a Munita, Jose M |e verfasserin |4 aut | |
| 700 | 1 | |a Ordoñez, Karen |e verfasserin |4 aut | |
| 700 | 1 | |a Weston, Greg |e verfasserin |4 aut | |
| 700 | 1 | |a Satlin, Michael J |e verfasserin |4 aut | |
| 700 | 1 | |a Valderrama-Beltrán, Sandra L |e verfasserin |4 aut | |
| 700 | 1 | |a Marimuthu, Kalisvar |e verfasserin |4 aut | |
| 700 | 1 | |a Stryjewski, Martin E |e verfasserin |4 aut | |
| 700 | 1 | |a Komarow, Lauren |e verfasserin |4 aut | |
| 700 | 1 | |a Luterbach, Courtney |e verfasserin |4 aut | |
| 700 | 1 | |a Marshall, Steve H |e verfasserin |4 aut | |
| 700 | 1 | |a Rudin, Susan D |e verfasserin |4 aut | |
| 700 | 1 | |a Manca, Claudia |e verfasserin |4 aut | |
| 700 | 1 | |a Paterson, David L |e verfasserin |4 aut | |
| 700 | 1 | |a Reyes, Jinnethe |e verfasserin |4 aut | |
| 700 | 1 | |a Villegas, Maria V |e verfasserin |4 aut | |
| 700 | 1 | |a Evans, Scott |e verfasserin |4 aut | |
| 700 | 1 | |a Hill, Carol |e verfasserin |4 aut | |
| 700 | 1 | |a Arias, Rebekka |e verfasserin |4 aut | |
| 700 | 1 | |a Baum, Keri |e verfasserin |4 aut | |
| 700 | 1 | |a Fries, Bettina C |e verfasserin |4 aut | |
| 700 | 1 | |a Doi, Yohei |e verfasserin |4 aut | |
| 700 | 1 | |a Patel, Robin |e verfasserin |4 aut | |
| 700 | 1 | |a Kreiswirth, Barry N |e verfasserin |4 aut | |
| 700 | 1 | |a Bonomo, Robert A |e verfasserin |4 aut | |
| 700 | 1 | |a Chambers, Henry F |e verfasserin |4 aut | |
| 700 | 1 | |a Fowler, Vance G |c Jr |e verfasserin |4 aut | |
| 700 | 1 | |a Arias, Cesar A |e verfasserin |4 aut | |
| 700 | 1 | |a van Duin, David |e verfasserin |4 aut | |
| 700 | 0 | |a Multi-Drug Resistant Organism Network Investigators |e verfasserin |4 aut | |
| 700 | 1 | |a Abbo, Lilian M |e investigator |4 oth | |
| 700 | 1 | |a Anderson, Deverick J |e investigator |4 oth | |
| 700 | 1 | |a Arias, Rebekka |e investigator |4 oth | |
| 700 | 1 | |a Arias, Cesar A |e investigator |4 oth | |
| 700 | 1 | |a Baum, Keri |e investigator |4 oth | |
| 700 | 1 | |a Bonomo, Robert A |e investigator |4 oth | |
| 700 | 1 | |a Chambers, Henry F |e investigator |4 oth | |
| 700 | 1 | |a Chen, Liang |e investigator |4 oth | |
| 700 | 1 | |a Chew, Kean Lee |e investigator |4 oth | |
| 700 | 1 | |a Cober, Eric |e investigator |4 oth | |
| 700 | 1 | |a Cross, Heather R |e investigator |4 oth | |
| 700 | 1 | |a De, Partha Pratim |e investigator |4 oth | |
| 700 | 1 | |a Desai, Samit |e investigator |4 oth | |
| 700 | 1 | |a Dhar, Sorabh |e investigator |4 oth | |
| 700 | 1 | |a Di Castelnuovo, Valentina |e investigator |4 oth | |
| 700 | 1 | |a Diaz, Lorena |e investigator |4 oth | |
| 700 | 1 | |a Dinh, An Q |e investigator |4 oth | |
| 700 | 1 | |a Doi, Yohei |e investigator |4 oth | |
| 700 | 1 | |a Earley, Michelle |e investigator |4 oth | |
| 700 | 1 | |a Eilertson, Brandon |e investigator |4 oth | |
| 700 | 1 | |a Evans, Beth |e investigator |4 oth | |
| 700 | 1 | |a Evans, Scott |e investigator |4 oth | |
| 700 | 1 | |a Fowler, Vance G |c Jr |e investigator |4 oth | |
| 700 | 1 | |a Fries, Bettina C |e investigator |4 oth | |
| 700 | 1 | |a Gao, Hainv |e investigator |4 oth | |
| 700 | 1 | |a Garcia-Diaz, Julia |e investigator |4 oth | |
| 700 | 1 | |a Garner, Omai B |e investigator |4 oth | |
| 700 | 1 | |a Greenwood-Quaintance, Kerryl |e investigator |4 oth | |
| 700 | 1 | |a Hanson, Blake |e investigator |4 oth | |
| 700 | 1 | |a Herc, Erica |e investigator |4 oth | |
| 700 | 1 | |a Hill, Carol |e investigator |4 oth | |
| 700 | 1 | |a Jacob, Jesse T |e investigator |4 oth | |
| 700 | 1 | |a Jiang, Jianping |e investigator |4 oth | |
| 700 | 1 | |a Kalayjian, Robert C |e investigator |4 oth | |
| 700 | 1 | |a Kanj, Souha S |e investigator |4 oth | |
| 700 | 1 | |a Kaye, Keith S |e investigator |4 oth | |
| 700 | 1 | |a Kim, Angela |e investigator |4 oth | |
| 700 | 1 | |a Komarow, Lauren |e investigator |4 oth | |
| 700 | 1 | |a Kreiswirth, Barry N |e investigator |4 oth | |
| 700 | 1 | |a Lauterbach, Courtney |e investigator |4 oth | |
| 700 | 1 | |a Li, Lanjuan |e investigator |4 oth | |
| 700 | 1 | |a Liu, Zhengyin |e investigator |4 oth | |
| 700 | 1 | |a Manca, Claudia |e investigator |4 oth | |
| 700 | 1 | |a Marimuthu, Kalisvar |e investigator |4 oth | |
| 700 | 1 | |a Marshall, Steven H |e investigator |4 oth | |
| 700 | 1 | |a McCarty, Todd |e investigator |4 oth | |
| 700 | 1 | |a Munita, Jose |e investigator |4 oth | |
| 700 | 1 | |a Ng, Oon Tek |e investigator |4 oth | |
| 700 | 1 | |a Oñate Gutierrez, Jose Millan |e investigator |4 oth | |
| 700 | 1 | |a Ordoñez, Karen |e investigator |4 oth | |
| 700 | 1 | |a Patel, Robin |e investigator |4 oth | |
| 700 | 1 | |a Paterson, David L |e investigator |4 oth | |
| 700 | 1 | |a Peleg, Anton |e investigator |4 oth | |
| 700 | 1 | |a Reyes, Jinnethe |e investigator |4 oth | |
| 700 | 1 | |a Rudin, Susan D |e investigator |4 oth | |
| 700 | 1 | |a Salata, Robert A |e investigator |4 oth | |
| 700 | 1 | |a Salcedo, Soraya |e investigator |4 oth | |
| 700 | 1 | |a Satlin, Michael J |e investigator |4 oth | |
| 700 | 1 | |a Schmidt-Malan, Suzannah |e investigator |4 oth | |
| 700 | 1 | |a Smitasin, Nares |e investigator |4 oth | |
| 700 | 1 | |a Spencer, Maria |e investigator |4 oth | |
| 700 | 1 | |a Stryjewski, Martin |e investigator |4 oth | |
| 700 | 1 | |a Su, Jiachun |e investigator |4 oth | |
| 700 | 1 | |a Tambyah, Paul Ananth |e investigator |4 oth | |
| 700 | 1 | |a Valderrama, Sandra |e investigator |4 oth | |
| 700 | 1 | |a van Duin, David |e investigator |4 oth | |
| 700 | 1 | |a Villegas Botero, Maria Virginia |e investigator |4 oth | |
| 700 | 1 | |a Wang, Minggui |e investigator |4 oth | |
| 700 | 1 | |a Waters, Mary |e investigator |4 oth | |
| 700 | 1 | |a Weston, Greg |e investigator |4 oth | |
| 700 | 1 | |a Wong, Darren |e investigator |4 oth | |
| 700 | 1 | |a Wortmann, Glenn |e investigator |4 oth | |
| 700 | 1 | |a Yang, Yang |e investigator |4 oth | |
| 700 | 1 | |a Yu, Yunsong |e investigator |4 oth | |
| 700 | 1 | |a Zhang, Fujie |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t The Lancet. Infectious diseases |d 2001 |g 22(2022), 3 vom: 02. März, Seite 401-412 |w (DE-627)NLM117564362 |x 1474-4457 |7 nnns |
| 773 | 1 | 8 | |g volume:22 |g year:2022 |g number:3 |g day:02 |g month:03 |g pages:401-412 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/S1473-3099(21)00399-6 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 22 |j 2022 |e 3 |b 02 |c 03 |h 401-412 | ||